ConductScience.org, home
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
API referenceFor AI assistants

Trial · NCT03396445

Participant flow208

How many started, completed or left each group, period by period.

1 to 20 of 208

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Treatment PeriodSTARTEDArm 1 Boserolimab 2 mg Q3W3
Treatment PeriodSTARTEDArm 1 Boserolimab 7 mg Q3W3
Treatment PeriodSTARTEDArm 1 Boserolimab 20 mg Q3W6
Treatment PeriodSTARTEDArm 1 Boserolimab 70 mg Q3W3
Treatment PeriodSTARTEDArm 1 Boserolimab 200 mg Q3W9
Treatment PeriodSTARTEDArm 1 Boserolimab 700 mg Q3W2
Treatment PeriodSTARTEDArm 1a Boserolimab 30 mg Q3W (Endometrial)14
Treatment PeriodSTARTEDArm 2 Boserolimab 2 mg Q3W + Pembrolizumab 200 mg Q3W3
Treatment PeriodSTARTEDArm 2 Boserolimab 7 mg Q3W + Pembrolizumab 200 mg Q3W3
Treatment PeriodSTARTEDArm 2 Boserolimab 20 mg Q3W + Pembrolizumab 200 mg Q3W4
Treatment PeriodSTARTEDArm 2 Boserolimab 70 mg Q3W + Pembrolizumab 200 mg Q3W7
Treatment PeriodSTARTEDArm 2 Boserolimab 200 mg Q3W + Pembrolizumab 200 mg Q3W14
Treatment PeriodSTARTEDArm 2a Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (TNBC)31
Treatment PeriodSTARTEDArm 2b Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W (Endometrial)15
Treatment PeriodSTARTEDArm 2c Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W (Endometrial)14
Treatment PeriodSTARTEDArm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC)10
Treatment PeriodSTARTEDArm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC)41
Treatment PeriodSTARTEDSwitch-over Arm 1 Boserolimab 2 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W0
Treatment PeriodSTARTEDSwitch-over Arm 1 Boserolimab 7 mg Q3W To Boserolimab 2 mg + Pembrolizumab 200 mg Q3W0
Treatment PeriodSTARTEDSwitch-over Arm 1 Boserolimab 20 mg Q3W To Boserolimab 7 mg + Pembrolizumab 200 mg Q3W0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03396445/flow

API referenceFor AI assistants